RNAI Technology


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1892. Categories: , .

Product Description

As advances in genetics ­continue to improve our understanding of ­disease, RNAi will have the opportunity to create entirely new classes of medicines.

Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the next five to 10 years. RNAi (RNA interference) represents a breakthrough in understanding how genes are turned on and off in cells.
“RNAi is a transformative discovery in modern biology that has already revolutionized biomedical research,” says John Maraganore, Ph.D., CEO of Alnylam Pharmaceuticals. “But the real opportunity with RNAi is to discover entirely new classes of medicines for patients. With RNAi therapeutics, we can harness the RNAi pathway and silence disease-causing genes that were previously…

Digital Exclusive Current RNA Research Efforts

RNAi At a Glance

Experts on this topic
Jim Jenson, Ph.D. CEO, Dicerna ­Pharmaceuticals, a private, venture-backed biopharmaceutical company developing novel therapeutic agents using proprietary technology that triggers RNA interference. For more information, visit
John Maraganore, Ph.D. CEO, Alnylam Pharmaceuticals Inc., a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. For more ­information, visit
Stuart W. Peltz, Ph.D. President and CEO, PTC Therapeutics Inc., a biopharmaceutical ­company focused on the discovery, ­development, and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control ­processes. For more information, visit
Louis M. Renzetti, Ph.D. VP and Global Head, RNA Therapeutics, Roche, a research-oriented healthcare group with core businesses in ­pharmaceuticals and diagnostics. For more ­information, visit
Kleanthis G. Xanthopoulos, Ph.D. ­President and CEO, Regulus Therapeutics Inc., a ­biopharmaceutical company aiming to discover, develop, and commercialize microRNA-based ­therapeutics. For more information, visit ­
Daniel Zurr, Ph.D. CEO and President of ­Quark Pharmaceuticals Inc., a development-stage ­pharmaceutical company discovering and ­developing novel RNAi-based therapeutics. For more information, visit ­